Results 1 to 10 of about 5,401 (184)

Curcumin-enhanced elvitegravir therapy mitigates neuroinflammation and cognitive deficits in EcoHIV mice [PDF]

Experimental Biology and Medicine
HIV-associated neurocognitive disorders (HAND) persist in up to 50% of people living with HIV (PLWH) despite effective antiretroviral therapy (ART), driven by chronic neuroinflammation, oxidative stress, and neuronal damage.
Sandip Godse, Lina Zhou, Namita Sinha, Mohd Salman, Tauheed Ishrat, Santosh Kumar   +5 more
doaj   +3 more sources

Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg [PDF]

Journal of the International AIDS Society
Introduction Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was efficacious and well tolerated in children/adolescents with HIV (aged ≥6 years, weighing ≥25 kg) in a Phase 2/3 study.
Eva Natukunda, Aditya H. Gaur, Pope Kosalaraksa, Elizabeth Hellström, Renate Strehlau, Afaaf Liberty, Stephanie Cox, Rory Leisegang, Ramesh Palaparthy, Susanne Crowe, Vinicius Vieira, Kathryn Kersey, Natella Rakhmanina   +12 more
doaj   +3 more sources

An Elvitegravir Nanoformulation Crosses the Blood–Brain Barrier and Suppresses HIV-1 Replication in Microglia

Viruses, 2020
Even with an efficient combination of antiretroviral therapy (ART), which significantly decreases viral load in human immunodeficiency virus type 1 (HIV-1)-positive individuals, the occurrence of HIV-1-associated neurocognitive disorders (HAND) still ...
Yuqing Gong, Santosh Kumar, Murali Yallapu   +2 more
exaly   +4 more sources

A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundNew multi-purpose prevention technology (MPT) products are needed to prevent human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV2).
Andrea R. Thurman, Louise A. Ouattara, Nazita Yousefieh, Peter L. Anderson, Lane R. Bushman, Xi Fang, Homaira Hanif, Meredith Clark, Onkar Singh, Gustavo F. Doncel   +9 more
doaj   +2 more sources

Stimulating Effect of Elvitegravir on Suicidal Erythrocyte Death [PDF]

Cellular Physiology and Biochemistry, 2016
Background/Aims: The antiviral drug Elvitegravir is used for the treatment of Human Immunodeficiency Virus (HIV) infections. The present study explored whether the drug is able to trigger eryptosis, the suicidal death of erythrocytes.
Rosi Bissinger, Abdulla Al Mamun Bhuyan, Elena Signoretto, Florian Lang   +3 more
doaj   +4 more sources

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Microbiology Spectrum, 2023
Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited.
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung   +15 more
doaj   +2 more sources

Curcumin enhances elvitegravir concentration and alleviates oxidative stress and inflammatory response

Scientific Reports, 2023
In this study, we investigated the potential of using curcumin (CUR) as an adjuvant to enhance the delivery of antiretroviral drug elvitegravir (EVG) across the BBB, and alleviate oxidative stress and inflammatory response, which are the major hallmark ...
Sandip Godse, Lina Zhou, Namita Sinha, Sunitha Kodidela, Asit Kumar, Udai P. Singh, Santosh Kumar   +6 more
doaj   +3 more sources

Hepatic steatosis associated with exposure to elvitegravir and raltegravir. [PDF]

Clinical Infectious Diseases, 2021
Moderate-to-severe hepatic steatosis in people living with HIV without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir and raltegravir.
D. Kirkegaard-Klitbo, M. T. Thomsen, M. Gelpi, F. Bendtsen, S. Nielsen, T. Benfield   +5 more
semanticscholar   +4 more sources

PLGA-Encapsulated Elvitegravir and Curcumin Modulates ART Penetration, Oxidative Stress, and Inflammation

Brain Sciences
Background/Objectives: HIV persists in central nervous system (CNS) reservoirs, where infected microglia and macrophages drive neuroinflammation, oxidative stress, and neuronal damage, contributing to HIV-associated neurocognitive disorder (HAND ...
Sandip Godse, Lina Zhou, Namita Sinha, Golnoush Mirzahosseini, Santosh Kumar   +4 more
doaj   +2 more sources

Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir

Antiviral Therapy
Background Integrase strand transfer inhibitors (INSTIs) have been associated with excess weight gain in people living with HIV compared to other antiretroviral agents. The mechanisms that underlie these effects are not well defined.
Richard Taylor Pickering, Archana Asundi, Alex Olson, Katie Soden, Daniel R Kuritzkes, Nina H Lin   +5 more
doaj   +2 more sources